Results 191 to 200 of about 2,275 (253)

The Evolving Role of Monomethyl Fumarate Treatment as Pharmacotherapy for Relapsing-Remitting Multiple Sclerosis. [PDF]

Cureus
Kaye AD, Lacey J, Le V, Fazal A, Boggio NA, Askins DH, Anderson L, Robinson CL, Paladini A, Mosieri CN, Kaye AM, Ahmadzadeh S, Shekoohi S, Varrassi G.   +13 more
europepmc   +1 more source

Psoriasis in Obese Patients: Pathophysiological Interactions, Clinical Consequences, and Therapeutic Implications. [PDF]

J Clin Med
Almeida-Silva G, Antunes J, Ferreira J, Filipe P.   +3 more
europepmc   +1 more source

Apparent Endoscopic Decrease in the Size of a Large Ulcerated Gastric Schwannoma After Helicobacter pylori Eradication Therapy: A Case Report

DEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Gastric subepithelial lesions (SELs) comprise a heterogeneous group of tumors, among which gastric schwannomas are rare and generally benign. We report a case of a large gastric schwannoma with ulceration and symptomatic anemia that showed an apparent endoscopic decrease in size following Helicobacter pylori eradication.
Takahito Awatsu, Daisuke Asaoka, Hirofumi Fukushima, Daishi Kabemura, Yusuke Nomoto, Osamu Nomura, Kazunori Kajino, Mariko Hojo, Akihito Nagahara   +8 more
wiley   +1 more source

Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study. [PDF]

Mult Scler
Nesbitt C, Sanfilippo P, Zhu C, Ozakbas S, Prat A, Girard M, Duquette P, Kalincik T, Roos I, Buzzard K, Skibina O, Foschi M, Surcinelli A, Lechner-Scott J, Patti F, Kermode AG, Fabis-Pedrini M, Carroll WM, Hodgkinson S, Grand'Maison F, Havrdova EK, Hradilek P, Habek M, Maimone D, Alroughani R, Vachova M, van Pesch V, Macdonell R, Spitaleri D, Khoury SJ, Gerlach O, de Gans K, McCombe P, Van Der Walt A, Butzkueven H, Jokubaitis V.   +35 more
europepmc   +1 more source

Health Literacy and Unmet Needs in Patients With Multiple Sclerosis: A Cross‐Sectional Study

Journal of Clinical Nursing, Volume 35, Issue 11, Page 4816-4827, November 2026.
ABSTRACT Aims To identify a correlation between unmet needs and HL levels in people with Multiple Sclerosis (pwMS) and to evaluate how sociodemographic characteristics influence HL levels and unmet needs. Design A cross‐sectional study. Methods The study was conducted using a questionnaire including the HLS19‐Q12 to assess HL and the Long‐term Unmet ...
Francesco Pastore, Barbara Forastefano, Valentina Simonetti, Tommaso Guerra, Giancarlo Cicolini, Pietro Iaffaldano, Dania Comparcini   +6 more
wiley   +1 more source

The Effect of Ozone Therapy on Psoriasis. [PDF]

Clin Case Rep
Aghaei M, Aghaei S, Shahmoradi Z, Nilforoushzadeh MA, Hossein Hejazi S.   +4 more
europepmc   +1 more source

Cyclic azapeptide CD36 ligand attenuates cardiac injury and reduces long‐chain fatty acid accumulation after myocardial ischemia–reperfusion in mice

FEBS Open Bio, Volume 16, Issue 10, Page 1958-1973, October 2026.
In a murine model of myocardial ischemia and reperfusion (MI/R), the CD36 azapeptide ligand MPE‐298 reduces cardiac injury and transiently lowers left ventricular long‐chain fatty acids (LCFAs) accumulation 3 h after reperfusion, accompanied by a decrease of oxidative stress and inflammation‐associated genes' expression in the heart and adipose tissue.
Jade Gauvin, Naghme Radmannia, David N. Huynh, Liliane Ménard, Caroline Daneault, Maïté Veilleux, Ahsanullah Ahsanullah, André C. Carpentier, William D. Lubell, Matthieu Ruiz, Huy Ong, Sylvie Marleau, Simon‐Pierre Gravel   +12 more
wiley   +1 more source

Late-Onset Neutropenia After Rituximab in Multiple Sclerosis: Incidence, Predictors, and Outcomes in a Retrospective Multicenter Cohort. [PDF]

Neurol Neuroimmunol Neuroinflamm
Hallberg S, Kallin S, Evertsson B, Boremalm M, de Flon P, Salzer J, Lycke J, Fink K, Svenningsson A.   +8 more
europepmc   +1 more source

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study

Annals of Neurology, Volume 100, Issue 4, Page 788-792, October 2026.
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies ...
Thomas Frisell, Sebastian Hedberg, Fredrik Piehl   +2 more
wiley   +1 more source